Intraventricular human immunoglobulin distributes extensively but fails to modify amyloid in a mouse model of amyloid deposition

Current Alzheimer Research

Volumn 11, Issue 7, 2014, Pages 664-671

  Joly Amado, Aurelie ^a   Brownlow, Milene ^a   Pierce, Jacob ^a   Ravipati, Advaitaa ^a   Showalter, Erin ^a   Li, Qingyou ^a   Gordon, Marcia N ^a   Morgan, Dave ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Behavioral testing; CD45; Congo red; Microglial activation; Radial arm water maze; Vaccination

Indexed keywords

AMYLOID PRECURSOR PROTEIN; IMMUNOGLOBULIN G; SODIUM CHLORIDE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; APP PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; FOREBRAIN; HIPPOCAMPUS; HISTOPATHOLOGY; LEARNING; MEMORY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STAINING; ANIMAL BEHAVIOR; BRAIN CORTEX; CORPUS STRIATUM; ENZYME LINKED IMMUNOSORBENT ASSAY; LATERAL BRAIN VENTRICLE; LOCOMOTION; NEUROPIL; PYRAMIDAL NERVE CELL; THALAMUS; WHITE MATTER; AGING; AMYLOIDOSIS; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MAZE TEST; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENTRICULAR; MAZE LEARNING; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; PLAQUE, AMYLOID;

EID: 84906903815     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140812114341     Document Type: Article

References (24)

1. Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63 (2011).
2. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 10: 115-9 (2010).
3. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 227: 167-74 (2010).
4. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta- amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75:1472-4 (2004).
5. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30: 1728-36 (2009).
6. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo- controlled, dose-finding trial. Lancet Neurol 12: 233-43 (2013).
7. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-5 (2000).
8. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23: 3745-51 (2003).
9. Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. Expert Rev Vaccines 3: 717-25 (2004).
10. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
11. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KL, et al. Time course of the development of Alzheimer- like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173: 183-95 (2002).
12. Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, et al. Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis 11: 165-81 (2013).
13. Anisman H. Time-dependent variations in aversively motivated behaviors: nonassociative effects of cholinergic and catechola- minergic activity. Psychol Rev 82: 359-85 (1975).
14. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc 1: 1671-9 (2006).
15. Nash KR, Lee DC, Hunt JB, Morganti JM, Selenica M-L, Moran P, et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 34:1540-8 (2013).
16. Lee DC, Ruiz CR, Lebson L, Selenica M-LB, Rizer J, Hunt JB, et al. Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging 34: 1610-20 (2013).
17. Herber D, Mercer M, Roth L, Symmonds K, Maloney J, Wilson N, et al. Microglial Activation is Required for A Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice. J Neuroimmune Pharm 2: 222-31 (2007).
18. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64: 743-53 (2005).
19. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflamm 7: 90 (2010).
20. Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, et al. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci 30: 9651-8 (2010).
21. Chauhan NB, Siegel GJ, Lichtor T. Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice. J Neurosci Res 78: 732-41 (2004).
22. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyper- phosphorylated tau aggregates via the proteasome. Neuron 43: 321-32 (2004).
23. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflamm 9: 105 (2012).
24. Sudduth TL, Greenstein A, Wilcock DM. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Abeta in APP/PS1 mice along a different time course than anti-Abeta antibodies. J Neurosci 33: 9684-92 (2013).